Pradžia › Berkito limfoma › Oregon
Berkito limfoma klinikiniai tyrimai Oregon
8 tyrimai dėl Berkito limfoma ieško dalyvių vietose Oregon.
Miestai Oregon
Oficialus tyrimo tekstas (anglų kalba)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- ir dar 1
Renkami dalyviai3 fazė
Amžius nuo 18 iki 39 · Visoms lytims · Atnaujinta 2026-10-02 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT03739814Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Renkami dalyviai2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-09-01 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Oregon Health & Science University, Portland
Renkami dalyviai2 fazė
Amžius nuo 7 iki 25 · Visoms lytims · Atnaujinta 2026-08-19 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-13 · NCT05544019Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.